Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction - Trial NCT05778084
Access comprehensive clinical trial information for NCT05778084 through Pure Global AI's free database. This Phase 4 trial is sponsored by Alexandria University and is currently Recruiting. The study focuses on Heart Failure With Reduced Ejection Fraction. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Alexandria University
Timeline & Enrollment
Phase 4
Dec 15, 2022
Dec 15, 2024
Primary Outcome
NT-ProBNP
Summary
This study aims to evaluate the relationship between NT-proBNP and empagliflozin effects in
 patients with chronic heart failure with mildly reduced ejection fraction (HFmrEF 41-49%) and
 reduced ejection fraction (HFrEF ≤40%) whether diabetic or non-diabetic patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05778084
Non-Device Trial